TrialThe Lancet. Oncology2017

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.

Beatrice Seddon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.